Pharsight

Lundbeck Pharms Llc patents expiration

1. Carnexiv patents expiration

CARNEXIV's oppositions filed in EPO
CARNEXIV Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9629797 LUNDBECK PHARMS LLC Parenteral carbamazepine formulation
Nov, 2028

(5 years from now)

US9770407 LUNDBECK PHARMS LLC Parenteral carbamazepine formulation
Nov, 2028

(5 years from now)

US8410077 LUNDBECK PHARMS LLC Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US7635773 LUNDBECK PHARMS LLC Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US9750822 LUNDBECK PHARMS LLC Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US9493582 LUNDBECK PHARMS LLC Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(9 years from now)

US11529357 LUNDBECK PHARMS LLC Injectable carbamazepine composition essentially free of 10-bromo-carbamazepine
Jan, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 7, 2023

Drugs and Companies using CARBAMAZEPINE ingredient

Market Authorisation Date: 07 October, 2016

Treatment: Replacement therapy for oral carbamazepine in adults with partial seizures with complex symptomatology; Replacement therapy for oral carbamazepine in adults with generalized tonic-clonic seizures; Rep...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

CARNEXIV family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic